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ABSTRACT
Objectives: Clinical trials of tumour necrosis factor
antagonists have raised questions about the potential risk
of certain serious adverse events (SAE). To assess the
safety of adalimumab in rheumatoid arthritis (RA) over
time and across five other immune-mediated inflamma-
tory diseases and to compare adalimumab malignancy
and mortality rates with data on the general population.
Methods: This analysis included 19 041 patients
exposed to adalimumab in 36 global clinical trials in RA,
psoriatic arthritis (PsA), ankylosing spondylitis (AS),
Crohn’s disease (CD), psoriasis and juvenile idiopathic
arthritis (JIA) to 15 April 2007. Events per 100 patient-
years were calculated using SAE reported after the first
dose to 70 days after the last dose. Standardised
incidence rates were calculated for malignancies using
national and state-specific databases. Standardised
mortality rates (SMR) were calculated for each disease
using data from the World Health Organization.
Results: Cumulative rates of SAE of interest in RA have
remained stable over time. Rates of SAE of interest for
PsA, AS, CD, psoriasis and JIA were similar to or lower
than rates for RA. Overall malignancy rates for
adalimumab-treated patients were as expected for the
general population. SMR across all six diseases indicated
that no more deaths occurred with adalimumab than
expected in the general population.
Conclusions: Based on 10 years of clinical trial
experience across six diseases, this safety report and the
established efficacy of adalimumab in these diseases
provide the foundation for a better understanding of its
benefit–risk profile.
Tumour necrosis factor (TNF) plays an important
roleinthepathogenesisofrheumatoidarthritis(RA),
juvenile idiopathic arthritis (JIA), psoriatic arthritis
(PsA), ankylosing spondylitis (AS), Crohn’s disease
(CD) and psoriasis. Anti-TNF therapies have proved
effective in these diseases, either as monotherapy or
in combination with other immunosuppressive
therapies. All three commercially available TNF
antagonists, adalimumab (Humira; Abbott
Laboratories, Abbott Park, Illinois, USA), etanercept
(Enbrel; Immunex, Thousand Oaks, California,
USA) and infliximab (Remicade; Centocor, Inc,
Malvern, Pennsylvania, USA), are indicated for RA,
PsA, AS and psoriasis.
1–15 Adalimumab and inflix-
imab are also indicated for CD; adalimumab and
etanercept are indicated for JIA.
16–21
Based on the results of clinical trials,
1–12 16–21
questions have arisen about the potential risk of
serious infections, including tuberculosis, and
malignancies with TNF antagonists.
22–24 Other
adverse events (AE) of interest that have been
reported following TNF antagonist treatment
include lupus-like syndromes, demyelinating dis-
orders and congestive heart failure (CHF).
25–29
Long-term data from an extensive number of
patients with different immune-mediated inflam-
matory diseases can provide further insight into
the safety of TNF blockade.
Adalimumab, the first fully human monoclonal
antibody targeted against TNF, was first adminis-
tered to a study patient in 1997.
30 We evaluated
safety data from approximately 10 years of clinical
trial experience with adalimumab in six diseases.
Our primary objectives were to: (1) extend the
results of the initial RA clinical trial safety analysis
by Schiff et al
31 through two additional years,
evaluating the stability of serious adverse event
(SAE) rates over time; (2) evaluate and compare the
safety of adalimumab in PsA, AS, JIA, CD and
psoriasis within the context of the established
safety profile in RA; and (3) evaluate malignancies
and mortality rates from adalimumab clinical trials
and compare them with rates from the general
population. This report represents the largest
clinical trial dataset of the three TNF antagonists,
and is the first comprehensive safety analysis of a
TNF antagonist across six immune-mediated
inflammatory diseases.
METHODS
Data were derived from 36 global clinical trials of
adalimumab, 19 in RA, three in PsA, three in AS,
one in JIA, five in CD and five in psoriasis,
including randomised controlled trials, open-label
trials and long-term extension studies to 15 April
2007. Inclusion criteria for these trials ensured that
the index disease was present and that patients had
active disease appropriate for clinical trial enrol-
ment. Exclusion criteria were generally standar-
dised and included: the presence of clinically active
tuberculosis, active listeriosis, acute or chronic
hepatitis B, or a history of hepatitis C; persistent
or severe infections requiring hospitalisation or
treatment with intravenous antibiotics 30 days
before baseline or oral antibiotics within 14 days of
baseline; a history of neurological symptoms
suggestive of a demyelinating disorder; a signifi-
cant history of cardiac, renal, neurological, psy-
chiatric, endocrinological, metabolic, or hepatic
disease that would adversely affect participation
in the study; a history of malignancy other than
carcinoma in situ of the cervix or successfully
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and a known history of HIV infection.
Rates of SAE of interest
Investigators reported AE occurring after the first dose of
adalimumab up to 70 days (five half-lives) after the last study
dose. SAE were defined as those that were fatal or life
threatening, those that required inpatient hospitalisation or
prolongation of existing hospitalisation and those that resulted
in persistent or significant disability or required medical/surgical
intervention to prevent another serious outcome.
32 If a patient
gave birth to a child with a congenital anomaly or birth defect,
experienced a miscarriage, or underwent an elective abortion,
these were also labelled SAE. SAE were coded using the Medical
Dictionary for Regulatory Activities (MedRA).
Thisanalysisfocusedongenerallyacceptedeventsofinterestfor
theanti-TNF class,whichinclude seriousinfections,tuberculosis,
opportunistic infections, demyelinating disorders, lupus-like
syndrome, CHF, malignancies, lymphomas and non-melanoma
skin cancer (NMSC). Predetermined search criteria were used to
identify events in these categories, and all cases underwent
medicalreview.Foreachdisease,SAErateswerereportedasevents
per 100 patient-years (number of events divided by the total
patient-years of exposure and multiplied by 100).
Malignancy and mortality data versus the general population
Standardised incidence rates (SIR) were calculated using the ratio
of the observed number of cancers to the expected number of
cancers for each cancer site. 95% CI for the SIR were calculated
based on the Poisson distribution.
33 The expected numbers of
cancersforSIRcalculationswerebasedontwodatasources:(1)5-
yearage-specificcancerincidenceratesobtainedfromtheNational
Cancer Institute (NCI) Surveillance Epidemiology and End
Results database (1993–2001) for all cancers other than NMSC
34
and (2) 10-year age-specific incidence rates for NMSC (basal cell
carcinoma (BCC) and squamous cell carcinoma (SCC)) from an
NCI survey of eight locations in the USA (1977–8).
35 Sensitivity
analyses were performed using expected NMSC rates from two
othersources:BCCandSCCincidenceratesinArizona(1996)and
SCC incidence rates in Minnesota (1984–92), states with
considerably discordant skin cancer rates.
36 37
A standardised mortality rate (SMR), the ratio of observed
deaths to expected deaths, for each disease was calculated using
the expected rates based on country-specific age and sex-
matched general population data from the World Health
Organization to 2002.
38 Deaths during clinical trials, whether
related to the study drug or not, were included in the analysis.
RESULTS
Baseline characteristics of patients are provided in table 1. A
total of 19 041 patients received adalimumab. Of these, 12 345
were patients with RA, of whom 1472 received adalimumab
therapy for at least 5 years. Rates of SAE of interest for each of
the six diseases are listed in table 2.
Stability of safety profile in RA over time
Cumulative SAE rates from 2002, 2004, 2005 and 2006
31 39–41
were comparable to those from 2007: serious infections (4.6–5.1
Table 1 Baseline characteristics of patients by specific diseases
Rheumatoid arthritis Psoriatic arthritis
Ankylosing
spondylitis
Juvenile
idiopathic
arthritis Psoriasis Crohn’s disease
N 12 345 837 1641 171 1819 2228
Mean age, years 53.8 48.4 43.2 11.8 44.1 38.3
Mean disease duration, years 10.6* 14.6* 11.1* 3.8 18.5 11.7*
Female, % 79.1 47.4 27.7 78.9 32.3 61.3
Median duration of exposure, years (range) 0.70 (0.04–9.03) 0.39 (0.04–3.53) 0.38 (0.04–3.04) 2.99 (0.04–4.50) 1.36 (0.04–4.01) 0.50 (0.04–4.42)
On concomitant immunosuppressants, % 61.8 55.6 17.8 49.7 0.3 40.2
On concomitant systemic steroids, % 58.6 19.1 15.4 21.6 1.2 35.3
From US sites, % 21.4 25.3 8.8 51.5 53.3 57.3
*Based on the following number of patients with available baseline disease duration information: rheumatoid arthritis, 11 984; psoriatic arthritis, 819; ankylosing spondylitis, 1640;
Crohn’s disease, 1933.
Table 2 SAE of interest, events/100 patient-years, as of 15 April 2007
Rheumatoid
arthritis
Psoriatic
arthritis
Ankylosing
spondylitis
Juvenile
idiopathic
arthritis Psoriasis
Crohn’s
disease
N 12 345 837 1641 171 1819 2228
Exposure (patient-years) 18 284.3 997.5 1255.2 398.4 2424.7 2373.7
Serious infections 4.65 2.81 1.11 2.76 1.32 5.18
Tuberculosis 0.29 0.30 0 0 0.12 0.13
Opportunistic infections 0.09 0 0 0 0 0.08
Histoplasmosis 0.03 0 0 0 0 0
Malignancies excluding lymphoma and
NMSC
0.76 0.30 0.08 0 0.49 0.46
Lymphoma 0.12 0.20 0.08 0 0 0.08
NMSC 0.17 0 0.08 0 0.12 0
Demyelinating disorder 0.05 0 0.08 0 0 0.13
Lupus-like syndrome 0.07 0 0 0 0 0.04
Congestive heart failure 0.23 0 0.16 0 0 0
NMSC, non-melanoma skin cancer; SAE, serious adverse event.
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patient-years), lymphomas (0.10–0.21 vs 0.12/100 patient-
years), demyelinating disease (0.05–0.08 vs 0.05/100 patient-
years) and lupus-like syndrome (0.05–0.10 vs 0.07/100 patient-
years). Of these events, serious infections remained the most
common.
SAE of interest across six immune-mediated inflammatory
diseases
Serious infections
The greatest rates of serious infections were observed in RA and
CD clinical trials (table 2). The risk of patients experiencing
their first serious infection was not greater at any one point
during the course of therapy (fig 1). The most commonly
reported serious infections were pneumonia for RA and abscess
for CD (intra-abdominal or gastrointestinal tract related).
Patients with early RA (disease duration ,3 years, mean
0.7 years) had a serious infection rate of 2.76/100 patient-years
compared with 4.91/100 patient-years in those with established
RA.
Tuberculosis rates for each of the six diseases were similar,
with the exception of AS and JIA, for which no cases of
tuberculosis have been reported. Among patients with RA,
extrapulmonary involvement was reported in 33 of the 53
tuberculosis cases.
Opportunistic infections
Most opportunistic infections reported in adalimumab clinical
trials did not fulfil the regulatory criteria for SAE as determined
by the investigators. Most commonly reported was oral
candidiasis. In RA, 17 opportunistic infections (0.09/100
patient-years) considered to be SAE occurred: six cases of
histoplasmosis; three cases of cytomegaloviral infections and
one case each of coccidioidomycosis, toxoplasmosis, listeriosis,
nocardiosis, aspergilloma, Pneumocystis jiroveci infection, oeso-
phageal candidiasis and candida sepsis. In CD, two cases (0.08/
100 patient-years) of opportunistic infections that were SAE
occurred, one case each of nocardiosis and coccidioidomycosis.
Opportunistic infections were infrequently reported among
patients with other immune-mediated inflammatory diseases:
six cases in PsA; eight in AS; one in JIA and five in psoriasis.
Nearly all reported events were oral candidiasis; none were SAE
(table 2). No cases of progressive multifocal leukoencephalo-
pathy have been reported in adalimumab clinical trials.
Demyelinating disorders
Few cases of demyelinating disorders were reported during
adalimumab clinical trials (table 2). Thirteen cases were
reported in RA studies: six cases of multiple sclerosis; two
Guillain–Barre ´ syndrome; two optic neuritis; two non-specific
demyelination and one optic nerve disorder. Ten (0.05/100
patient-years) were SAE. One optic neuritis event (0.08/100
patient-years), also an SAE, was reported during AS trials. Three
cases of optic neuritis and one case of multiple sclerosis were
reported in CD studies. Three (0.13/100 patient-years) were
SAE. No demyelinating disorders were observed in JIA, PsA and
psoriasis trials.
Lupus-like syndrome
Lupus-like syndrome was infrequent among adalimumab-
treated patients (table 2). Thirty-five events in the lupus-like
syndrome category occurred during RA trials, only 12 (0.07/100
patient-years) were SAE: six cases of lupus-like syndrome; three
systemic lupus erythematosus; two cutaneous lupus erythema-
tosus and one antiphospholipid antibody syndrome. Six events
were reported in CD trials. Only one case (0.04/100 patient-
years) of lupus-like syndrome was an SAE. One patient in the
psoriasis clinical development programme developed cutaneous
lupus erythematosus, which was not considered an SAE by the
investigator. No cases were reported in PsA, AS and JIA trials.
Most patients with RA or CD who reported lupus-like
syndrome SAE presented with cutaneous manifestations or
serositis. None had internal organ involvement (eg, nephritis).
Adalimumab malignancy and mortality rates versus data from
the general population
Malignancies
The risk of malignancy was not greater at any one point
during the course of adalimumab therapy (fig 1). The SIR by
Figure 1 (A) Time to first serious infection, all adalimumab patients.
(B) Time to first malignancy other than non-melanoma skin cancer
(NMSC), all adalimumab patients. Overall scales are from 1.0 to 0.0; the
portion of the scale from 0.7 to 1.0 has been emphasised for clarity.
Numbers along the x-axis represent the numbers of patients who were at
risk for each time point, ie, those still in the study who had not yet
experienced the event.
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supplemental table 1 (available online only). The SIR for
malignancies in clinical trials for all diseases combined was
0.83 (95% CI 0.72 to 0.96). The SIR for lymphomas reported in
fig 2 were based on 23 cases (19 cases of non-Hodgkin’s
lymphoma and four cases of Hodgkin’s lymphoma) from RA,
two from PsA, two from CD and one from AS trials (fig 2). No
lymphomas were reported during JIA and psoriasis trials. The
observed number of lymphoma cases was significantly greater
than the expected number only in the RA trials (SIR 2.98; 95%
CI 1.89 to 4.47). The rate for the early RA population was
0.09/100 patient-years compared with 0.12/100 patient-years
in established RA.
The SIR for NMSC varied depending on which comparator
database was employed (fig 3). Based on the NCI database, SIR
(95% CI) for BCC (1.24 (1.01 to 1.51)) and SCC (1.97 (1.34 to
2.80)) for RA and SCC for CD (6.27 (2.02 to 14.6)) and psoriasis
(3.84 (1.54 to 7.92)) were significantly greater than 1.0. These
SIR were no longer significantly greater than 1.0 when either
the Arizona or Minnesota rates were employed for comparison,
with the exception of SCC for CD (3.97 (1.28 to 9.26)), based on
the Minnesota database. The BCC and SCC SIR for all other
diseases, regardless of the comparator database, did not
demonstrate statistically significant differences between
observed and expected numbers of cases (SIR ,1 or 95% CI
included 1.0). In clinical trials for all diseases considered
collectively and in RA trials alone, other than lymphomas and
NMSC, no other type of malignancy had a significantly greater
incidence (SIR .1.0 and 95% CI did not include 1.0) compared
with the general population (data not shown).
Figure 2 Standardised incidence rates (SIR) for all malignancies and lymphomas for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing
spondylitis (AS), psoriasis (Ps) and Crohn’s disease (CD). *All malignancies other than non-melanoma skin cancer. {Based on data from 12 344
patients. All other diseases included all the patients in the analysis. {No lymphomas were observed in psoriasis. No malignancies were observed in
juvenile idiopathic arthritis.
Figure 3 Standardised incidence rates (SIR) for non-melanoma skin cancer (NMSC) using three comparator databases. *Based on data from 12 344
patients. All other diseases included all the patients in the analysis. No malignancies were observed for juvenile idiopathic arthritis. AS, ankylosing
spondylitis; CD, Crohn’s disease; NCI, National Cancer Institute; Ps, psoriasis; PsA, psoriatic arthritis; RA, rheumatoid arthritis.
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SMR for patients treated with adalimumab for each of the six
diseases, regardless of sex, were all less than 1.0 (ie, the number
of deaths observed during treatment with adalimumab was less
than what would be expected in the general population; fig 4).
No deaths were reported in the JIA or AS clinical programmes.
DISCUSSION
This was the first comprehensive safety review of a TNF
antagonist in all six of its approved disease indications. Our
results extend the findings of previous long-term adalimumab
safety reports for RA
31 39–41 by showing that the frequency of
SAE of interest appeared stable after additional patient-years of
exposure in RA, and by demonstrating that the safety profile of
adalimumab in RA was comparable to PsA, AS, psoriasis, JIA
and CD clinical trials.
Compared with the established and well-accepted overall
safety profile of adalimumab in RA, data from clinical trials in
other diseases yielded overall similar SAE rates. However,
serious infections occurred more frequently in patients with
RA or CD, whereas rates were lower in patients with the four
other diseases evaluated. Potential reasons for these observa-
tions include inherent differences in risks of various AE between
the diseases studied, differences in the severity and duration of
disease, comorbidities and the use of concomitant medications
(eg, corticosteroids or other immunosuppressants).
42–45 Serious
infections occurred less frequently in patients with early RA
than in the established RA population, suggesting that the risk
of serious infections may be lower in patients who are treated
earlier in their disease course.
The rate of serious infections in adalimumab RA trials was
within the range reported in RA populations before the
availability of TNF antagonists (3.1–9.6/100 patient-years)
42 45
and was comparable to that reported from long-term etanercept
clinical trials (4.2/100 patient-years).
46 Dixon et al
22 did not find
increased rates of serious infections in patients with RA in the
anti-TNF cohort of the British Society for Rheumatology
Biologics Registry when considering the entire duration of
therapy, but noted an increased early risk (within the first
90 days of therapy commencement) compared with the disease-
modifying antirheumatic drug cohort. Our analysis did not
indicate that the occurrence of serious infections was clustered
around any point in the course of adalimumab therapy,
including the period immediately after the initiation of
treatment.
As of this analysis, tuberculosis has not been reported for
patients from adalimumab clinical trials in JIA or AS. There are
two plausible explanations for this observation. First, only the
AS development programme required re-screening for tubercu-
losis at year 2 and those who had seroconverted received
prophylaxis. Second, on the basis of the positive effects of
screening and prophylaxis, tuberculosis cases observed thus far
with adalimumab therapy have generally been thought to have
resulted from the reactivation of latent tuberculosis.
31 Given
that none of the patients in the JIA trial were purified protein
derivative positive at study entry and that the JIA and AS
populations are relatively young, tuberculosis reactivation was
unlikely.
In 10 years of adalimumab RA clinical trials, SAE of interest
other than serious infections continued to be of relatively low
frequency and have not increased over time. SAE reports of
demyelinating disorders, lupus-like syndrome and CHF have
also not been observed in PsA, psoriasis and JIA. Other than the
potential differences in predisposition or risks for these events
between the diseases studied, another possible explanation is
the smaller population sizes of these clinical development
programmes compared with those for RA and CD.
Overall, the risk of malignancies with adalimumab in global
clinical trials was not increased when compared with the
general population. No malignancies were reported in JIA
clinical trials. Risks associated with long-term use should be
examined in future investigations that go beyond the scope of
these long-term extension trials.
The observed number of cases of lymphoma in RA clinical
trials was significantly greater than that expected for the
general population. Patients with RA have an inherent twofold
increased risk of developing lymphomas irrespective of therapy
compared with the general population, especially those patients
with greater disease activity for whom a 70-fold increased risk
has been reported.
47–49 Therefore, it is not unexpected to observe
an SIR greater than 1.0 for patients with RA in the adalimumab
clinical trial database compared with the general population.
Figure 4 Standardised mortality rates (SMR) for rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (Ps) and Crohn’s disease (CD). No
deaths occurred in juvenile idiopathic arthritis or ankylosing spondylitis. *No deaths occurred among female patients with psoriasis.
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developing NMSC.
50 Wolfe and Michaud
24 reported an increased
risk of NMSC (odds ratio 1.5; 95% CI 1.2 to 1.8) and melanoma
(odds ratio 2.3; 95% CI 0.9 to 5.4) in patients with RA treated
with biological agents (infliximab, etanercept, adalimumab, or
anakinra) compared with patients not on biological therapy. For
adalimumab, NMSC SIR varied according to the comparator
database, with SIR generally greater using the NCI than the
Arizona or Minnesota datasets. This is most likely because the
Arizona and Minnesota datasets cover a later time period than
the NCI, which demonstrated an increase in US skin cancer
rates after the 1970s. Although the CI overlapped, the point
estimate for the SCC SIR in psoriasis was consistently lower
than for CD, regardless of the comparator database employed.
Given the use of psoralen and ultraviolet A light (a known risk
factor for NMSC)
51 in patients with psoriasis and dermatolo-
gists’ heightened awareness of screening for these lesions, this
suggests that adalimumab and phototherapy/topical therapies
do not seem to act synergistically to increase the risk of NMSC
in patients with psoriasis.
In terms of mortality rates, the SMR from adalimumab trials
were less than 1.0 for all six diseases. No more deaths occurred
with adalimumab than in the general population. The SMR in
adalimumab-treated patients with RA was lower than the SMR
previously reported for general RA populations naive to anti-
TNF therapy in observational studies conducted in the USA,
Canada and Spain.
52–54 The SMR for PsA, CD and psoriasis from
the adalimumab database were also lower than SMR previously
published for these diseases.
55–57
Several factors should be considered in drawing definitive
conclusions about the SMR and SIR in adalimumab clinical
trials. First, the inclusion/exclusion criteria of each study have
probably selected a patient sample with fewer or less severe
comorbidities. Furthermore, there is a possibility that those
remaining in the study at the end of the follow-up period were
healthier, confounding the seemingly stable results over time.
Second, clinical trial participation also implies better follow-up
and closer monitoring of patients. Third, the control of
inflammation in RA with adalimumab may potentially lower
some of the risks of mortality (ie, cardiovascular disease).
Therefore, although these data provide information about the
overall safety profile of adalimumab, conclusions beyond their
primary intent in characterising safety should be made with
caution.
Important insights about the safety of TNF antagonists may
be gained from 10 years of adalimumab clinical trial experience
across several immune-mediated inflammatory diseases in more
than 19 000 patients. Although SAE such as tuberculosis,
demyelinating disorders, malignancies and lupus-like syndromes
require careful diligence, the most frequently reported events are
still serious infections. Physicians and patients need to be
vigilant for the signs and symptoms of infections when
initiating or continuing biological therapy, including the
implementation of appropriate tuberculosis screening before
treatment. Our observations indicate that the safety profile of a
drug such as adalimumab is probably influenced by a combina-
tion of drug-based toxicity, disease-inherent risks for certain
SAE and baseline patient characteristics.
The adalimumab data presented in this report support its
safety for long-term use and in patients across six different
immune-mediated inflammatory diseases. Given the confirmed
efficacy and substantial benefits of adalimumab in these
conditions, the risk of therapy should be weighed against the
risk of uncontrolled inflammatory disease and its long-term
sequelae. The extent of the safety data generated by this
analysis provides physicians with further information to
enhance their benefit–risk discussions with patients.
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